Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC), platform, Harpoon is developing a pipeline of novel T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Harpoon's first drug candidate, HPN424, is currently in Phase 1 clinical trial as a treatment for prostate cancer.

Information Technology

Harpoon Therapeutics

Che-Leung Law

Wendy Chang

Luke Walker

Banmeet Anand

Grace Wang

Alpana Naresh

Meghan Kellam

Rick Austin

Annie Winterhall

Bryan Lemon

The Scientific Team at Harpoon Therapeutics focuses on the discovery and development of proprietary T cell engagers using the TriTAC platform. The team conducts cutting-edge research, protein analytics, and formulation development to advance novel immunotherapies, predominantly targeting solid tumors and hematologic malignancies. Their efforts support the clinical progression of drug candidates like HPN424 through various phases of trials.

Scientific Team

Clinical Operations Team

Leadership Team

Scientific Team

About

Team members

Other teams at Harpoon Therapeutics

Clinical Operations Team

Leadership Team